Age-related macular degeneration treatment market to reach $10 billion by 2023
The market for treatments of age-related macular treatment market across seven major countries will almost double in value from $5.1 billion in 2013 to $10.1 billion by 2023, according to research and consulting firm GlobalData.
The company’s report finds that the expansion across the USA, UK, Germany, France, Spain, Italy and Japan at a compound annual growth rate (CAGR) of 7.1% will be driven by new therapies entering the market and a global aging society. This will lead to increasing numbers of elderly people developing the age-related retinal disease.
Catherine Daly, GlobalData’s analyst covering neurology and ophthalmology, said the global AMD treatment market is dominated by anti-vascular endothelial growth factor (anti-VEGF) drugs, including Swiss drug majors Roche's (ROG: SIX) and Novartis' (NOVN: VX) Lucentis (ranibizumab) and Roche's Avastin (bevacizumab; used off-label), and Bayer’s (BAYN: DE) Eylea (aflibercept), which together accounted for 98% of sales for AMD in 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze